Peter Illes Selected Research

Purinergic P2X7 Receptors

2/2022	Beyond Seizure Control: Treating Comorbidities in Epilepsy via Targeting of the P2X7 Receptor.
1/2022	A Possible Causal Involvement of Neuroinflammatory, Purinergic P2X7 Receptors in Psychiatric Disorders.
1/2021	Increasing Efficiency of Repetitive Electroacupuncture on Purine- and Acid-Induced Pain During a Three-Week Treatment Schedule.
1/2019	Pathological ATPergic Signaling in Major Depression and Bipolar Disorder.
1/2019	The P2X7 receptor: a new therapeutic target in Alzheimer's disease.
1/2017	Pilocarpine-Induced Status Epilepticus Increases the Sensitivity of P2X7 and P2Y1 Receptors to Nucleotides at Neural Progenitor Cells of the Juvenile Rodent Hippocampus.
1/2016	Purinergic receptors in embryonic and adult neurogenesis.
10/2014	P2X7 receptor: an emerging target in central nervous system diseases.
1/2013	Anoxic depolarization of hippocampal astrocytes: possible modulation by P2X7 receptors.
1/2013	Neurochemical Changes in the Mouse Hippocampus Underlying the Antidepressant Effect of Genetic Deletion of P2X7 Receptors.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter Illes Research Topics

Disease

12	Pain (Aches) 01/2021 - 05/2003
10	Ischemia 08/2020 - 07/2004
6	Neuroinflammatory Diseases 02/2022 - 03/2005
6	Parkinson Disease (Parkinson's Disease) 01/2021 - 03/2006
6	Alzheimer Disease (Alzheimer's Disease) 01/2021 - 03/2006
5	Neuralgia (Stump Neuralgia) 01/2022 - 03/2007
5	Necrosis 01/2021 - 07/2004
4	Epilepsy (Aura) 02/2022 - 03/2005
3	Inflammation (Inflammations) 02/2022 - 08/2006
3	Chronic Pain 01/2022 - 01/2013
3	Multiple Sclerosis 01/2021 - 01/2020
3	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2021 - 01/2020
3	Gliosis 04/2014 - 05/2003
3	Hypoxia (Hypoxemia) 01/2013 - 03/2006
2	Brain Diseases (Brain Disorder) 02/2022 - 10/2005
2	Anhedonia 02/2022 - 01/2013
2	Mental Disorders (Mental Disorder) 01/2022 - 10/2014
2	Pathologic Processes 01/2021 - 03/2006
2	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2020 - 08/2020
2	Status Epilepticus (Complex Partial Status Epilepticus) 08/2020 - 01/2017
2	Mood Disorders (Mood Disorder) 01/2019 - 10/2014
2	Brain Injuries (Brain Injury) 01/2016 - 08/2006
2	Infarction (Infarctions) 01/2011 - 07/2004
2	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2011 - 07/2004
1	Shock 02/2022
1	Major Depressive Disorder (Major Depressive Disorders) 02/2022
1	Necrotizing Enterocolitis 01/2022
1	Colitis 01/2022
1	Primary Immunodeficiency Diseases 01/2022
1	Headache (Headaches) 01/2022
1	Bacterial Infections (Bacterial Infection) 01/2022
1	Autism Spectrum Disorder 01/2022
1	Common Variable Immunodeficiency 01/2022
1	COVID-19 01/2022
1	Rheumatoid Arthritis 12/2021
1	Sepsis (Septicemia) 12/2021
1	Crohn Disease (Crohn's Disease) 12/2021
1	Gout 01/2021
1	Hyperuricemia 01/2021
1	Basal Ganglia Diseases (Basal Ganglia Disease) 11/2020
1	Heart Failure 10/2019
1	Atrial Fibrillation 10/2019
1	Systolic Heart Failure 10/2019

Drug/Important Bio-Agent (IBA)

24	Adenosine Triphosphate (ATP)IBA 02/2022 - 07/2004
13	Purinergic P2X7 ReceptorsIBA 02/2022 - 07/2004
7	Adenosine (Adenocard)FDA LinkGeneric 02/2022 - 07/2004
7	Purinergic Receptors (Receptors, Purine)IBA 11/2020 - 07/2004
4	Glutamic Acid (Glutamate)FDA Link 01/2022 - 11/2004
3	Analgesics (Analgesic Drugs)IBA 01/2022 - 01/2019
3	ChemokinesIBA 01/2022 - 01/2019
3	Messenger RNA (mRNA)IBA 01/2022 - 09/2005
3	CytokinesIBA 01/2022 - 01/2019
3	purineIBA 01/2021 - 01/2020
3	AcidsIBA 01/2021 - 01/2011
3	Pharmaceutical PreparationsIBA 10/2019 - 09/2006
3	LigandsIBA 10/2018 - 03/2005
3	NucleotidesIBA 01/2017 - 04/2014
3	pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acidIBA 01/2013 - 05/2003
2	3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphateIBA 02/2022 - 12/2005
2	Sucrose (Saccharose)IBA 02/2022 - 01/2013
2	Oxygen (Dioxygen)IBA 01/2022 - 12/2005
2	AntibodiesIBA 01/2022 - 07/2004
2	Purinergic P2X3 ReceptorsIBA 01/2021 - 10/2007
2	Amphetamine (Amfetamine)FDA LinkGeneric 03/2006 - 12/2004
2	Proteins (Proteins, Gene)FDA Link 09/2005 - 07/2004
2	Glial Fibrillary Acidic ProteinIBA 07/2004 - 05/2003
1	tilivallineIBA 01/2022
1	Enterotoxins (Enterotoxin)IBA 01/2022
1	XenobioticsIBA 01/2022
1	Pregnane X ReceptorIBA 01/2022
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2022
1	Cytotoxins (Cytolysins)IBA 01/2022
1	tilimycinIBA 01/2022
1	Pattern Recognition ReceptorsIBA 01/2022
1	Immunoglobulin G (IgG)IBA 01/2022
1	Immunoglobulin IsotypesIBA 01/2022
1	LipopolysaccharidesIBA 01/2022
1	Morphine (MS Contin)FDA LinkGeneric 01/2022
1	NitrogenIBA 01/2022
1	AntigensIBA 01/2022
1	Peptide Hydrolases (Proteases)FDA Link 01/2022
1	ProstaglandinsIBA 01/2022
1	Pathogen-Associated Molecular Pattern MoleculesIBA 01/2022
1	SuperantigensIBA 01/2022
1	BNT162 VaccineIBA 01/2022
1	VaccinesIBA 01/2022
1	rho GTP-Binding Proteins (rho GTP-Binding Protein)IBA 12/2021
1	MitogensIBA 12/2021
1	Phospholipases A2 (Phospholipase A2)IBA 12/2021
1	Phosphotransferases (Kinase)IBA 12/2021
1	PurinesIBA 01/2021
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021
1	IonsIBA 08/2020
1	Adenosine Diphosphate (ADP)IBA 01/2020
1	Purinergic P2X ReceptorsIBA 01/2020
1	Enzyme Inhibitors (Inhibitors, Enzyme)IBA 01/2020

Therapy/Procedure

4	Therapeutics 01/2022 - 10/2007
3	Lasers (Laser) 01/2011 - 07/2004
2	Acupuncture Points (Acupuncture Point) 01/2021 - 01/2020
2	Electroacupuncture 01/2021 - 01/2020